<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01677455</url>
  </required_header>
  <id_info>
    <org_study_id>9090-11</org_study_id>
    <nct_id>NCT01677455</nct_id>
  </id_info>
  <brief_title>An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer</brief_title>
  <acronym>Enchant</acronym>
  <official_title>An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synta Pharmaceuticals Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synta Pharmaceuticals Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if ganetespib (STA-9090) is effective in the
      treatment of patients with HER2+ or triple negative breast cancer who have not received prior
      systemic treatment in the metastatic setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Week 12</time_frame>
    <description>Objective response rate is based on RECIST criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response and progression free survival</measure>
    <time_frame>Every six weeks until progression</time_frame>
    <description>Progressive disease based on RECIST criteria. CT scans at week 6, week 12 and every 6 weeks thereafter for the duration of the study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Breast Cancer</condition>
  <condition>HER-2 Positive Breast Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment</condition>
  <arm_group>
    <arm_group_label>HER2+ breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple negative breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Closed to enrollment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ER/PR+ Refractory to Prior Hormonal Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ganetespib</intervention_name>
    <description>Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle.</description>
    <arm_group_label>HER2+ breast cancer</arm_group_label>
    <arm_group_label>Triple negative breast cancer</arm_group_label>
    <arm_group_label>ER/PR+ Refractory to Prior Hormonal Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed diagnosis of invasive breast cancer.

          -  Stage IV disease.

          -  Documented HER2 and hormonal receptor status per protocol, ER/PR+ patients must be
             refractory to at least one prior hormonal treatment.

          -  ECOG Performance status 0-1.

          -  Measurable disease per RECIST (1.1).

          -  Adequate hematological function per protocol.

          -  Adequate hepatic function per protocol.

          -  Adequate renal function per protocol.

          -  Negative serum pregnancy test at study entry for patients of childbearing potential.

          -  Ability to understand and sign written consent and to comply with the study protocol.

        Exclusion Criteria:

          -  Presence of active or untreated CNS metastases as determined by MRI/CT scan performed
             during screening.

          -  Active malignancies other than MBC within the last 5 years except adequately treated
             in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin.

          -  Bone as the only site of metastatic disease from breast cancer.

          -  Prior radiotherapy to the only area of measurable disease. NOTE: Radiotherapy to a
             limited area other than the sole site of measurable disease is allowed, if received
             prior to initiation of ganetespib treatment. Patients must have completed treatment
             and recovered from all acute treatment-related toxicities prior to administration of
             first dose of ganetespib.

          -  Pregnancy or lactation.

          -  Known serious cardiac illness.

          -  Uncontrolled intercurrent illness per protocol.

          -  Other severe acute or chronic medical condition or abnormality that may increase the
             risk associated with study participation or study drug administration, or may
             interfere with the interpretation of study results, or that in the judgment of the
             investigator would make the patient inappropriate for entry into the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>Altanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceutical Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>Rosario Santa Fe</city>
        <zip>S2000KZE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>Brussels</city>
        <zip>B-1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceutical Investigative Site</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceutical Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-GU</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-Gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmacuetical Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-GU</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-Gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceutical Investigative Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceutical Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceutical Investigative Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG51PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceuticals Investigative Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synta Pharmaceutical Investigative Site</name>
      <address>
        <city>Peterborough</city>
        <zip>PE3 9GZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Korea, Republic of</country>
    <country>Peru</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2012</study_first_submitted>
  <study_first_submitted_qc>August 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2012</study_first_posted>
  <last_update_submitted>November 4, 2015</last_update_submitted>
  <last_update_submitted_qc>November 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hsp90 inhibitor</keyword>
  <keyword>ganetespib</keyword>
  <keyword>STA 9090</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

